GENETIC TECHNOLOGIES LIMITED — AGM Information 2018

Nov 28, 2018

==> picture [596 x 144] intentionally omitted <==

ASX ANNOUNCEMENT 29 November 2018

2018 Annual General Meeting

Melbourne, Australia; 29 November 2018 : Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”) is pleased to release the attached slide show presentation which will be delivered by its Interim Chief Executive Officer, Dr Paul Kasian, at the Company’s 2018 Annual General Meeting to be held at approximately 10.30 am this morning at 60-66 Hanover Street, Fitzroy, Victoria, Australia.

FOR FURTHER INFORMATION PLEASE CONTACT

Dr Paul Kasian

Jason Wong (USA)

Chairman and Interim CEO Blueprint Life Science Group Genetic Technologies Limited +1 (415) 375 3340, Ext. 4 + 61 3 8412 7000

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company embracing blockchain technologies across Genomic testing platforms. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead product, BREVAGen plus[®] , is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. For more information, please visit www.brevagenplus.com and www.phenogensciences.com.

Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For more information, please visit www.gtgcorporate.com

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.

Genetic Technologies Limited • Website : www.gtglabs.com • Email : info@gtglabs.com ABN 17 009 212 328 Registered Office • 60-66 Hanover Street Fitzroy Victoria 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone +61 3 8412 7000 • Fax +61 3 8412 7040

==> picture [631 x 478] intentionally omitted <==

GENETIC TECHNOLOGIES LIMITED

DISEASE RISK ASSESSMENT ON A GLOBAL SCALE

1

Forward Looking Statements

This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business achievements/performance of Genetic Technologies Limited and certain of the plans and objectives of its management. These statements are statements that are not historical facts.

Words such as “should”, “expects”, “anticipates”, “estimates”, “believes” or similar expressions, as they relate to Genetic Technologies Limited, are intended to identify forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Genetic Technologies’ current expectations and assumptions as to future events and circumstances that not accurate. There may prove is no guarantee that the expected events, trends or results will actually occur. in such or could cause Any changes assumptions expectations actual results to differ materially from current expectations.

2

Global healthcare spending is expected to reach $8.7 trillion by 2020.

Chronic disease accounts for 84% of healthcare spending.

==> picture [79 x 79] intentionally omitted <==

==> picture [79 x 79] intentionally omitted <==

==> picture [79 x 79] intentionally omitted <==

By 2020, 50 percent of Cancer global health care Cardiovascular expenditures will be Respiratory spent on these diseases:

The number of diabetes sufferers globally is expected to rise from 415 million to 642 million by 2040. Urbanization Chronic disease is Sedentary fueled by: lifestyles Changing diets

https://www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-lshc-hc-outlook-2018.pdf

3

Targeted screening reduces the cost of healthcare.

Early detection reduces the need for expensive, late-stage care. Limited screening resources can be targeted to those at increased risk.

4

Our flagship test, BREVAGen plus ®, predicts a woman’s risk of developing breast cancer.

5

BREVAGen plus ® allows providers to target limited resources to women who are most likely to develop breast cancer.

==> picture [79 x 79] intentionally omitted <==

==> picture [79 x 79] intentionally omitted <==

==> picture [79 x 79] intentionally omitted <==

Screening Medication Lifestyle

6

Additional screening tests are in development.

==> picture [853 x 341] intentionally omitted <==

7

Respected collaborators accelerate development.

The University of Melbourne is Australia’s peak research university. Our collaboration with Professor John Hopper led to our NHMRC Grant. The National Health and Medical Research Council is Australia's peak funding body for medical research.

==> picture [425 x 194] intentionally omitted <==

Ohio State University Ohio State University operates a clinical genetics service and is a leader in predictive genetic research for breast cancer. GTG is collaborating with Amanda Toland, Director of Clinical Genetics and a leader in the field of genetic risk for breast cancer. Together, we are exploring polygenic risk as a means to more informed decision-making for women with BRCA mutations.

8

• Comprehensive healthcare plan for 1.5 billion people

• Disease prevention to control costs

Healthy China 2030

• GTG genetic tests predict an individual’s risk of developing disease.

• Healthcare resources directed to people most at risk.

• Early intervention and less costly treatment.

9

==> picture [594 x 345] intentionally omitted <==

• Part of the Hainan Free Trade Zone Initiative

• Allows foreign companies to safely introduce IP and repatriate profits

Through our partnership with Zishan Health, GTG has been invited to participate.

Hainan Medical Pilot Zone

10

==> picture [594 x 345] intentionally omitted <==

• Part of the Hainan Free Trade Zone Initiative

• Allows foreign companies to safely introduce IP and repatriate profits

Through our partnership with Zishan Health, GTG has been invited to participate.

Hainan Medical Pilot Zone

11

Zishan Health Consultancy

==> picture [58 x 58] intentionally omitted <==

==> picture [58 x 58] intentionally omitted <==

==> picture [58 x 58] intentionally omitted <==

==> picture [58 x 58] intentionally omitted <==

Fast-track access to the Chinese FDA

Connections into the Chinese healthcare sector

Track record of introducing non-Chinese companies into the Hainan Free Trade Zone

In-country sales and marketing, both in Hainan and other provinces

12

Advancing genomics on the blockchain

==> picture [79 x 79] intentionally omitted <==

==> picture [79 x 79] intentionally omitted <==

==> picture [79 x 79] intentionally omitted <==

Development of region-specific tests where data will be managed on the blockchain Combining GTG core technology with blockchain capabilities Continuing to work with Blockchain Global to identify new opportunities

13

==> picture [241 x 144] intentionally omitted <==

----- Start of picture text -----

Refreshed Board
----- End of picture text -----

==> picture [240 x 144] intentionally omitted <==

----- Start of picture text -----

eCommerce Platform
----- End of picture text -----

==> picture [240 x 144] intentionally omitted <==

----- Start of picture text -----

R&D to develop new
tests
----- End of picture text -----

==> picture [594 x 54] intentionally omitted <==

==> picture [241 x 145] intentionally omitted <==

----- Start of picture text -----

Global Expansion
----- End of picture text -----

==> picture [545 x 145] intentionally omitted <==

----- Start of picture text -----

While these initiatives impacted our ability to generate
short-term revenue, we eliminated the cost of an
ineffective sales force, focused on R&D and initiated the
partnerships that will secure our global future.
----- End of picture text -----

2018: Aligning Structure with Strategy

==> picture [289 x 126] intentionally omitted <==

14

Thank You

==> picture [131 x 131] intentionally omitted <==

Paul Kasian Chairman and CEO Email: paul.kasian@gtglabs.com Web: www.gtgcorporate.com

15